

1. Name of the Medicinal Product

Vastarel® OD 40 mg

Vastarel® OD 80 mg

2. Qualitative and Quantitative Composition

Each Vastarel® OD 40 mg, prolonged-release hard capsule contains 40 mg of trimetazidine dihydrochloride

Each Vastarel® OD 80 mg, prolonged-release hard capsule contains 80 mg of trimetazidine dihydrochloride

Excipient with known effect:

Vastarel® OD 40 mg, prolonged-release hard capsule contains Sucrose: 16.87 mg per capsule


Vastarel® OD 80 mg, prolonged-release hard capsule contains Sucrose: 33.75 mg per capsule

For the full list of excipients, see section 6.1.


3. Pharmaceutical Form

Prolonged-release hard capsules.

Vastarel® OD 40 mg, prolonged-release hard capsule.

Hard capsule with a white body and an white cap with a printed grey Servier logo  and “40” on it.

Vastarel® OD 80 mg, prolonged-release hard capsule.

Hard capsule with a white body and an white cap with a printed grey Servier logo  and “80” on it.

4. Clinical Particulars

4.1 Therapeutic indications

Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.

4.2 Posology and method of administration

Posology

The dose is one capsule of 80 mg of trimetazidine once daily during breakfast.

The benefit of the treatment should be assessed after three months and trimetazidine should be discontinued if there is no treatment response.

Special populations

Patients with renal impairment

In patients with moderate renal impairment (creatinine clearance [30-60] ml/min) (see sections 4.4 and 5.2), the recommended dose is reduced by half *ie* 1 capsule of 40 mg in the morning during breakfast.

Elderly patients

Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function (see section 5.2). In patients with moderate renal impairment (creatinine clearance [30-60] ml/min), the recommended dose is reduced by half *ie* 1 capsule of 40 mg in the morning during breakfast. Dose titration in elderly patients should be exercised with caution (see section 4.4).

Paediatric population:

The safety and efficacy of trimetazidine in children aged below 18 years have not been established. No data are available.

Method of administration

Capsule must be taken orally without opening it, once daily *i.e.* one in the morning during breakfast

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Parkinson disease, parkinsonian symptoms, tremors, restlessleg syndrome, and other related movement disorders,
- Severe renal impairment (creatinine clearance < 30ml/min).

4.4 Special warnings and precautions for use

This medicine is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina or myocardial infarction, nor in the pre-hospital phase or during the first days of

hospitalisation.

In the event of an angina attack, the coronaropathy should be reevaluated and an adaptation of the treatment considered (medicinal treatment and possibly revascularisation).

Trimetazidine can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients. In doubtful cases, patients should be referred to a neurologist for appropriate investigations.

The occurrence of movement disorders such as parkinsonian symptoms, restlessleg syndrome, tremors, gait instability should lead to definitive withdrawal of trimetazidine.

These cases have a low incidence and are usually reversible after treatment discontinuation. The majority of the patients recovered within 4 months after trimetazidine withdrawal. If parkinsonian symptoms persist more than 4 months after drug discontinuation, a neurologist opinion should be sought.

Falls may occur, related to gait instability or hypotension, in particular in patients taking antihypertensive treatment (see section 4.8).

Caution should be exercised when prescribing trimetazidine to patients in whom an increased exposure is expected:

- moderate renal impairment (see sections 4.2 and 5.2),
- elderly patients older than 75 years old (see section 4.2)

This drug contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

No drug interactions have been identified.

4.6 Fertility, pregnancy and lactation

Pregnancy:

There are no data from the use of trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3.) As a precautionary measure, it is preferable to avoid the use of trimetazidine during pregnancy.

Breastfeeding:

It is unknown whether trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.

Fertility

Reproductive toxicity studies have shown no effect on fertility in female and male rats (see section 5.3)

4.7 Effects on ability to drive and use machines

Trimetazidine does not have haemodynamic effects in clinical studies, however cases of dizziness and drowsiness have been observed in post-marketing experience (see section 4.8), which may affect ability to drive and use machines.

4.8 Undesirable effects

Adverse reactions, defined as adverse events considered at least possibly related to trimetazidine treatment are listed below using the following convention frequency: very common ($\geq 1/10$); common ($\geq 1/100$ to $<1/10$); uncommon ($\geq 1/1,000$ to $<1/100$); rare ($\geq 1/10,000$ to $<1/1,000$); very rare ($<1/10,000$); not known (cannot be estimated from the available data).

System Organ Class	Frequency	Preferred Term
Nervous system disorders	Common	Dizziness, headache
	Not known	Parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restlessleg syndrome, other related movement disorders, usually reversible after treatment discontinuation
	Not known	Sleep disorders (insomnia, drowsiness)
Ear and labyrinth disorders	Not known	Vertigo
Cardiac disorders	Rare	Palpitations, extrasystoles, tachycardia
Vascular disorders	Rare	Arterial Hypotension, Orthostatic hypotension that may be associated with malaise, dizziness or fall, in particular in patients taking antihypertensive treatment, flushing
Gastrointestinal disorders	Common	Abdominal pain, diarrhoea, dyspepsia, nausea and vomiting
	Not known	Constipation

Skin and subcutaneous tissue disorders	Common	Rash, pruritus, urticaria.
	Not known	Acute generalized exanthematus pustulosis (AGEP), angioedema
General disorders and administration conditions	Common	Asthenia
Blood and lymphatic system disorders	Not known	Agranulocytosis Thrombocytopenia Thrombocytopenic purpura
Hepatobiliary disorders	Not known	Hepatitis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system

4.9 Overdose

Limited information is available on trimetazidine overdose. Treatment should be symptomatic.

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other cardiovascular antianginal drug,
ATC code: C01EB15

Mechanism of action

By preserving energy metabolism in cells exposed to hypoxia or ischaemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst maintaining cellular homeostasis.

Trimetazidine inhibits β -oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. In an ischaemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the β -oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.

Pharmacodynamic effects

In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels. Anti-ischemic effects are achieved without concomitant haemodynamic effects.

Clinical efficacy and safety

Clinical studies on trimetazidine have demonstrated its efficacy and safety in the treatment of patients with chronic angina, either alone or when the benefit from other antianginal medicinal products was insufficient.

In a 426-patients randomized, double blind, placebo-controlled study (TRIMPOL-II), trimetazidine (60mg/day) added to metoprolol 100mg daily (50 mg b.i.d) for 12 weeks significantly improved statistically exercise tests parameters and clinical symptoms as compared to placebo: total exercise duration +20.1s, $p= 0.023$, total workload +0.54 METs, $p=0.001$, time to 1-mm ST-segment depression +33.4s, $p=0.003$, time to onset of angina +33.9s, $p<0.001$, angina attacks/week -0.73, $p=0.014$ and short acting nitrates consumption/week, -0.63, $p=0.032$, without hemodynamic changes.

In 223 patients randomized, double blind, placebo-controlled study (Sellier), one 35 mg trimetazidine modified release tablet (b.i.d.) added to 50 mg atenolol (o.d.) for 8 weeks produced a significant increase (+34.4s, $p=0.03$) in the time to 1-mm ST-segment depression in exercise tests, in a sub-group of patients ($n=173$), when compared to placebo, 12 hours after taking the drug. A significant difference was also evidenced for the time to onset of angina pectoris ($p=0.049$). No significant difference between groups could be found for the other secondary endpoints (total exercise duration, total workload and clinical endpoints).

In a 1962 patients three-month randomised, double-blinded study (Vasco study) on top of atenolol 50 mg/d, two dosages of trimetazidine (70 mg/d and 140 mg/d) were tested versus placebo. In the overall population, including both asymptomatic and symptomatic patients, trimetazidine failed to demonstrate a benefit on both ergometric (total exercise duration, time to onset of 1mm ST and time to onset angina) and clinical endpoints. However, in the subgroup of symptomatic patients ($n= 1574$) trimetazidine (140 mg) significantly improved total exercise duration (+23.8 s versus +13.1 s placebo; $p=0.001$) and time to onset of angina (+46.3 s versus +32.5 s placebo; $p=0.005$).

In a 165 patients three-month randomised, double-blind acceptability

study on top of both routine antianginal therapies and secondary prevention therapy, the safety profile of trimetazidine 80 mg once daily was shown to be similar to that of trimetazidine MR 35 mg bid. No unexpected adverse event was reported and the study showed no concern regarding the once daily intake of trimetazidine 80 mg.

5.2 Pharmacokinetic properties

Absorption

After oral administration of trimetazidine 80mg capsule, trimetazidine PK profile is flat with a peak of trimetazidine concentration reached around 14 hours after drug intake. Over dosing interval i.e. 24 hours the plasma concentration remains for 15 hours at levels above or equal to 75% of the maximum concentration. Steady state is reached by the third dose intake (3 days).

Food intake has no effect on trimetazidine PK after administration of the 80mg formulation.

Distribution

The volume of distribution is 4.8 l/kg; protein binding is low (16%).

Elimination

Trimetazidine is primarily eliminated in the urine, mainly as unchanged form. The elimination half- life is on average 7 hours in healthy young volunteers and 12 hours in elderly (more than 65 years).

Total clearance of trimetazidine mainly consists of renal clearance which is directly correlated to creatinine clearance and, to a lesser extent, of liver clearance which is reduced with age.

Special populations

Elderly: The elderly may have increased trimetazidine exposure due to age-related decrease in renal function. A dedicated pharmacokinetic study performed in elderly 75-84 years or very elderly (≥ 85 years) participants showed that moderate renal impairment (creatinine clearance between 30 and 60 ml/min) increased respectively by 1.0 and 1.3 fold the Trimetazidine exposure in comparison to younger participants (30-65 years) with moderate renal impairment.

A specific clinical study carried out in an elderly population (older than 75 years old) using a dosage of 2 tablets of trimetazidine MR 35mg per day taken in 2 doses, analysed by a kinetic population method, showed on average a 2-fold increase in plasma exposure in patients with severe renal impairment (creatinine clearance below 30ml/min) as compared to those

with a creatinine clearance above 60 ml/min.

No safety concern was observed in the elderly population as compared to the general population.

Renal impairment: Trimetazidine exposure is increased on average by 1.7-fold in patients with moderate renal impairment (creatinine clearance between 30 and 60 ml/min), and on average by 3.1-fold in patients with severe renal impairment (creatinine clearance below 30ml/min) as compared to healthy volunteers, with normal renal function.

No safety concern was observed in this population as compared to the general population.

Paediatrics: The pharmacokinetics of trimetazidine has not been studied in the paediatric population (<18 years old).

5.3 Preclinical safety data

Chronic toxicity studies conducted by the oral route in dogs (5 to 40 mg.kg⁻¹.d⁻¹) and rats (5 to 200 mg.kg⁻¹.d⁻¹), showed a good safety profile.

Neither embryo-foetotoxic effect nor teratogenicity were detected in mice and in rabbits. A general study on reproduction and embryogenesis in 3 generations of rats showed no anomalies.

The genotoxic potential was thoroughly assessed with in vitro studies including the evaluation of the mutagenic and clastogenic potential and one in vivo study. All tests were negative.

6. Pharmaceutical Particulars

6.1 List of excipients

Capsule content:

Sugar sphere containing sucrose and maize starch

Hypromellose

Ethyl cellulose

Tributyl acetyl citrate

Talc

Magnesium stearate

Vastarel® OD 40 mg, prolonged-release hard capsule

Capsule shell:

Gelatin

Titanium dioxide (E171),

Printing Ink

Shellac (E904)

Titanium dioxide (E171)

Iron oxide black (E172)

Potassium hydroxide (E525)

Propylene Glycol (E1520)

Ammonium hydroxide 28% (E527)

Vastarel® OD 80 mg, prolonged-release hard capsule

Capsule shell:

Gelatin

Titanium dioxide (E171)

Red iron oxide (E172)

Printing Ink

Shellac-Glaze (E904)

Titanium dioxide (E171)

Simethicone

Propylene Glycol (E1520)

Ammonium hydroxide 28% (E527)

6.2 Incompatibilities

Not Applicable

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store below 30°C.

6.5 Nature and contents of container

Cartons of 30, 60 and 90 hard capsules in blister consisting of a foil of polyamide -aluminium - PVC and a foil of aluminium.

Not all of these pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder and manufacturing site addresses

Marketing Authorisation Holder

Les Laboratoires Servier
50 rue Carnot
92284 Suresnes cedex
France

Manufacturing Site Address

Egis Pharmaceuticals PLC,
H-9900 Körmend Mátyás Király u 65,
Hungary.

8. Marketing authorisation number(s)

H2024/CTD8043/15324 Vastarel® OD 40 mg
H2024/CTD8016/15298 Vastarel® OD 80 mg

9. Date of first authorisation/renewal of the authorisation

Vastarel® OD 40 mg – 16-Feb.-2024
Vastarel® OD 80 mg - 23-Feb.-2024

10. Date of revision of the text

Nov-2024